A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

You may not be if

• 1. Known or suspected hypersensitivity to any of the IPs, including budesonide, or excipients, including lactose
• 2. Systemic steroid use within the 6 weeks before Visit 1
• 3. Concomitant chronic respiratory disease (including current sleep apnea)
• 4. History or clinical suspicion of any clinically relevant or active disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study, or any other safety concerns in the opinion of the Investigator
• 5. Use of prohibited medications that cannot be stopped during the entire period of the study (starting Visit 1).
• 6. Subjects with \<80% eDiary compliance during Run in Period at Visit 3
• 7. ACQ-5 of ≥3 at Visit 1, Visit 2, or Visit 3
• 8. Daily rescue use of SABA ≥12 puffs for ≥3 consecutive days at any time during Run-in Period, before randomisation
• 9. Any clinically important abnormalities in rhythm, conduction or morphology of the digital ECG at rest and any abnormalities in the digital ECG (at Visit 1 or Visit 3) that, as considered by the Investigator, may interfere with the interpretation of QT interval corrected (QTc) interval changes
• 10. Prolonged QT interval corrected using Fridericia's formula (QTcF) ≥450 msec based on ECG at Visit 1 or Visit 3; or family history of long QT syndrome
• 11. PR (PQ) interval prolongation (\>240 msec), intermittent second or third degree atrial-ventricular (AV) block or AV dissociation at Visit 1 or Visit 3
• 12. Subjects with implantable cardiac defibrillator and subjects with sustained symptomatic ventricular and/or atrial tachyarrhythmia
• 13. Subjects with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society Class II, or a myocardial infarction or stroke within 6 months before Visit 1
• 14. History of hospitalisation within 12 months before Visit 1 caused by heart failure or a diagnosis of heart failure higher than New York Heart Association Class II
• 15. Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) at Visit 1
• 16. Donation of blood (≥ 450 mL) within 3 months or donation of plasma within 14 days before Visit 1
• 17. Suspected poor capability to follow instructions of the study, as judged by the Investigator
• 18. Previous participation or prior screen failure in the current study, or participation in any other research study within 1 month prior to Visit 1
• 19. Subject under treatment with biologicals such as monoclonal antibodies or chimeric biomolecules including omalizumab, mepolizumab, and reslizumab within 6 months or 5 half-lives before Visit 1, whichever is longer
• 20. Subject treated with any investigational drug within 30 days (or 5 half-lives, whichever is longer) prior to Visit 1
• 21. Positive drug screening result that cannot be justified by subject's medical history and its relevant treatment (over-the-counter product or a valid prescription), or history of or current alcohol or drug abuse (including marijuana and marijuana-containing valid prescriptions), as judged by the Investigator
• 22. Planned in-patient surgery, major dental procedure or hospitalisation during the study
• 23. Pregnant woman or lactating woman
• 24. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, contract research organisation staff and/or staff at the study centre)
• 25. Suspicion of Gilbert's syndrome
• 26. Vulnerable persons (eg, persons kept in detention)